These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17044658)

  • 1. Informed consent in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial: a survey of collaborating physicians.
    Fukui T; Rahman M; Morita S; Sakamoto J
    Hypertens Res; 2006 Jul; 29(7):471-4. PubMed ID: 17044658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
    Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
    Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
    Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
    Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
    Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
    Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicians' attitudes towards and reasons for participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
    Rahman M; Morita S; Fukui T; Sakamoto J
    J Epidemiol; 2005 Mar; 15(2):38-40. PubMed ID: 15762092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CASE-J].
    Fukui T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():449-53. PubMed ID: 16981578
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
    Ohashi H; Takagi H
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
    Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
    Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease.
    Staessen JA; Richart T; Birkenhäger WH
    Eur Heart J; 2009 May; 30(10):1164-6. PubMed ID: 19363059
    [No Abstract]   [Full Text] [Related]  

  • 14. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
    Sugiura R; Ogawa H; Oka T; Koyanagi R; Hagiwara N;
    Am J Cardiol; 2012 Feb; 109(4):576-80. PubMed ID: 22100194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of angiotensin II receptor antagonist on heart failure].
    Matsumori A
    Nihon Rinsho; 2004 Jan; 62(1):203-10. PubMed ID: 14737854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.
    Ogihara T; Fujimoto A; Ueshima K; Nakao K; Saruta T
    J Am Geriatr Soc; 2011 Jan; 59(1):180-1. PubMed ID: 21226700
    [No Abstract]   [Full Text] [Related]  

  • 18. [E-COST].
    Kanno Y; Suzuki H
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():480-5. PubMed ID: 16981581
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
    Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on cognition and prognosis in the elderly].
    Kohara K
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():425-30. PubMed ID: 16981574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.